Skip to Content


Active Substance: efalizumab
Common Name: efalizumab
ATC Code: L04AA21
Marketing Authorisation Holder: Serono Europe Limited
Active Substance: efalizumab
Status: Withdrawn
Authorisation Date: 2004-09-20
Therapeutic Area: Psoriasis
Pharmacotherapeutic Group: Immunosuppressants

Therapeutic Indication

Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).

The marketing authorisation for Raptiva has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.